RPG Life Sciences Limited has informed the Exchange that Record date for the purpose of DI is 19-Jun-2026.
RPGLIFE · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 13.5 pts more than Nifty Microcap 250 and 13.4 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
RPG Life Sciences reported FY2025-26 standalone revenue of Rs. 70,752 lakhs, up 8.3% from Rs. 65,343 lakhs in FY2024-25. However, profit after tax declined significantly to Rs. 11,517 lakhs from Rs. 18,324 lakhs (down 37%), driven by lower exceptional items. The prior year included a one-time gain of Rs. 10,018 lakhs from land assignment. This year, exceptional items included Rs. 12,623 lakhs from land sale, Rs. 2,475 lakhs net insurance recovery from a fire incident, partially offset by Rs. 1,169 lakhs labour code impact and Rs. 916 lakhs intangible asset write-off. The Board recommended a dividend of Rs. 24 per share (300%), subject to shareholder approval. Auditor gave an unmodified (clean) opinion. The company also appointed Dr. Pratit Samdani as an Additional Non-Executive Independent Director for 5 years.
The 37% PAT decline despite 8% revenue growth reflects the absence of large one-time gains seen in the previous year. The strong dividend payout signals management confidence, but investors should focus on core operating performance excluding exceptional items when evaluating the stock.